The first randomized, placebo-controlled trial of intrajejunal levodopa provides support for the benefits of continuous dopaminergic drug delivery. Motor fluctuations in patients with advanced Parkinson disease were markedly improved. In clinical practice, the symptomatic benefits of this treatment need to be weighed carefully against its adverse effect profile.
Nature Reviews Neurology 2014- advanced online pubblication
Nessun commento:
Posta un commento